Options Forecast Based on Pattern Recognition: Returns up to 546.67% in 1 Year

Options Forecast

This forecast is part of the Options Package, as one of I Know First’s algorithmic trading tools. The Options Forecast includes Top 10 daily predictions for the best options to buy for a total of 20 stocks with bullish and bearish signals:

  • Top 10 Call Options
  • Top 10 Put Options

Options
Package Name: Options
Recommended Positions: Long
Forecast Length: 1 Year (6/11/20 – 6/11/21)
I Know First Average: 208.62%
Options Forecast
Options Forecast chart

I Know First’s State of the Art Algorithm accurately forecasted 10 out of 10 trades in this Options Package for the 1 Year time period. The prediction with the highest return was CLDX, at 546.67%. Additional high returns came from NVAX and DNR, at 366.37% and 306.02% respectively. The package had an overall average return of 208.62%, providing investors with a premium of 175.48% over the S&P 500’s return of 33.14% during the same period.

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.